MichaelE.RyttingMD
Pediatric Hematology & Oncology • El Paso, TXAssociate Professor, Pediatrics and Leukemia
Dr. Rytting is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4845 Alameda Ave
El Paso, TX 79905Phone+1 915-215-5700Fax+1 915-215-8872
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 1994 - 1997- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1990 - 1994
University of Michigan Medical SchoolClass of 1990
Certifications & Licensure
MI State Medical License 1993 - 2026
TX State Medical License 1994 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Treatment of Tumors of the Choroid Plexus Epithelium Start of enrollment: 2005 Sep 02
- Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Start of enrollment: 2006 Sep 12
- Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 171 citationsFinal report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lympho...Naval Daver, Deborah A. Thomas, Farhad Ravandi, Jorge E. Cortes, Rebecca Garris
Haematologica. 2015-05-01 - 83 citationsAugmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).Michael Rytting, Deborah A. Thomas, Susan O'Brien, Farhad Ravandi-Kashani, Elias J. Jabbour
Cancer. 2014-12-01 - 121 citationsSalvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymp...Elias Jabbour, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nicholas J. Short
JAMA Oncology. 2017-08-31
Abstracts/Posters
- Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax RegimensMichael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaMichael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
